This study explores whether lymphoma cell adhesion-induced B cell-activating factor (BAFF) expression in bone marrow stromal cells (BMSCs) protects B lymphoma cells from apoptosis. We first showed protection of lymphoma cells from apoptosis by conditioned medium of a stromal cell-lymphoma cell coculture, either spontaneous or induced by mitoxantrone, implying a role for soluble factor(s) in lymphoma cell survival.
Introduction
Stromal cells are an essential component of the bone marrow microenvironment that regulates or supports tumor survival. Bone marrow stroma has long been recognized as a 'sanctuary site' for lymphoma cells during traditional chemotherapy. 1 Although the cell adhesion-mediated drug resistance (CAM-DR) phenotype was observed for cytotoxic drugs when hematologic malignant cells adhered to the bone marrow, the molecular mechanism associated with CAM-DR could be unique for each type of cancer. The contributions and molecular mechanisms of CAM-DR depend on the type of malignant cell, type of stress used to induce cell death, and the specific microenvironmental element to which cancer cells adhere. The bone marrow microenvironment consists of a diverse milieu of cytokines, growth factors, hormones and components of bone marrow stromal cells (BMSCs) and extracellular matrix. Many of these factors may contribute to the CAM-DR phenotype, and indeed, many of these factors may play different roles in different hematologic malignancies (leukemia vs lymphoma vs myeloma). For instance, lymphoma is often located in the lymph node, extra nodal sites or bone marrow, whereas leukemia and myeloma are almost always located in the bone marrow. Several growth factors including interleukin-6, insulin-like growth factor-1, insulin and fibroblast growth factor are known to promote myeloma survival and may contribute CAM-DR in myeloma. Granulocyte-macrophage colony-stimulating factor may be involved in CAM-DR in acute myeloid leukemia. However, the extent to which soluble factor(s) and specific factor(s), contribute to increased survival during the cellular response to therapy, as well as the molecular mechanisms involved in lymphoma, are unclear to date.
B cell-activating factor (BAFF), also known as BLyS protein (B lymphocyte stimulator), TALL-1 (TNF and apoptosis ligandrelated leukocyte-expressed ligand-1), zTNF4, TNFS20 (TNF superfamily member) and THANK (TNF homolog that activates apoptosis, nuclear factor (NF)-kB and c-Jun NH 2 -terminal kinase) are members of the TNF superfamily of cytokines that was first identified from a human neutrophil/ monocyte-derived complementary DNA library. 2 BAFF protein is known to specifically target B lymphocytes, promote B-cell proliferation, activation and differentiation, and enhance B-lymphocyte survival. It thereby stimulates immunoglobulin production both in vitro and in vivo. 3 In normal mice receiving injections of BAFF, lymphoid compartments in the spleen undergo marked expansion, and plasma levels of immunoglobulins increase significantly. 3 The role of BAFF in B-cell homeostasis became evident from studies in BAFF null 4, 5 and BAFF transgenic mice. [6] [7] [8] Mice lacking BAFF have extreme reductions of mature B cells in peripheral blood, whereas mice overexpressing BAFF have increased numbers of mature splenic and lymph node B cells, elevated immunoglobulin levels, and manifestations of autoimmune disease. 8 The mechanism whereby BAFF exerts these effects is by improving the survival of peripheral B cells, 9, 10 which is thought to allow the escape of B cells from cytotoxic apoptosis, leading to autoimmune disease. Taken together, these findings have led to the proposal that BAFF plays a critical role in maintaining B-cell homeostasis, with insufficient signaling by BAFF resulting in B-cell deficiency and excessive signaling causing B-cell disorders.
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B cell-activating factor exerts its effect by binding to three known receptors: transmembrane activator and calcium modulator cyclophilin ligand interactor (TACI), B-cell maturation antigen (BCMA) and BAFF-receptor/BLyS receptor 3 (BAFF-R). 8, [12] [13] [14] [15] BAFF-R and BCMA expression are restricted to B cells, whereas TACI is found on both B cells and activated T cells. BAFF receptors appear to be expressed on immunoglobulin-positive B cells but not on immunoglobulin-negative pre-and pro-B cells. It has been shown that BAFF receptors are expressed on a broad range of tumor cells of B-cell lineage, including multiple myeloma (MM), large B-cell lymphoma, follicular B-cell lymphoma, chronic lymphocytic leukemia and Burkitt's lymphoma. 16 BAFF was shown to bind to various diffuse large cell, mantle and marginal zone B lymphomas at levels similar to those observed in normal mature B cells, whereas lower levels were found in follicular non-Hodgkin's lymphoma (NHL) and B-chronic lymphocytic leukemia (B-CLL). 16, 17 Most B-CLL cells express BAFF-R RNA and a subset actually displays BAFF on their respective surfaces, raising the exciting possibility that autocrine BAFF may be a component of B-CLL survival. 17, 18 Elevated levels of BAFF were detected in serum from NHL patients. 16 Serum levels of BAFF and APRIL (a proliferation-inducing ligand) were increased about fivefold in patients with MM as compared with healthy donors. 19 Although most B lymphoma cells exhibit characteristics consistent with prolonged cell survival in vivo, and BAFF is implicated in this process through an autocrine mechanism, these cells often undergo spontaneous apoptosis when cultured in vitro. This observation suggests that the microenvironment that supports prolonged B-cell survival in vivo is not generally recapitulated in vitro. Moreover, this phenomenon suggests that the selective survival advantage enjoyed by B lymphoma cells is not entirely autonomous, raising the possibility of manipulating B-cell survival by iatrogenic means. More recently, 20 we showed protection of lymphoma cells from apoptosis by conditioned medium of a stromal cell-lymphoma cell coculture, either spontaneous or induced by mitoxantrone, implying a role of soluble factor(s) in lymphoma cell survival. We anticipate that macrophage and BMSC-derived BAFF directly regulates lymphoma cell survival and attenuates cytotoxic apoptosis in NHLs. In this study, we show that BMSCs secrete abundant BAFF and define the functional significance of BAFF in survival and drug resistance of human NHLs. Inhibition of BAFF and its signaling pathways may therefore be of therapeutic value for these lymphomas.
Materials and methods

Cell lines, cell cultures and patient lymphoma samples
The human lymphoma cell lines, SUDHL-10 and SUDHL-4 (CD19 þ , CD20 þ , CD10À, CD5À, CD3À, CD44À, diffuse large B-cell lymphoma), were provided by Dr M Raffeld, National Cancer Institute, Bethesda, USA, and Jeko-1 (CD19 þ , CD20 þ , CD10À, CD5 þ , CD3À, CD44À, cyclin D1 þ , mantle cell lymphoma) was provided by Dr R Lai, University of Alberta, Edmonton, Canada. The human BMSC line, HS-5, was obtained from the American Type Culture Collection (Rockville, MD, USA). The cells were grown in suspension in RPMI 1640 (Cellgro, Fischer Scientific Pittsburgh, PA, USA), supplemented with 5% fetal bovine serum (Omega Scientific, Turzana CA, USA), and 1% (v/v) penicillin (100 U/ml), streptomycin (100 U/ml) and 1% (v/v) L-glutamine (GIBCO-BRL, Grand Island, NY, USA). Cells were fed after 4 days by adding one-half the volume of the complete medium, and then were fed at weekly intervals by complete replacement of the medium until a confluent monolayer was developed. Primary BMSC cultures were established from BM aspirates of healthy donors after suitable informed consent. Briefly, mononuclear cells obtained after Ficoll-Hypaque density centrifugation were suspended in a-minimal essential medium (a-MEM, GibcoBRL, Grand Island, NY, USA) supplemented with 10% fetal bovine serum and antibiotics at a concentration of 1 Â 10 6 cells per ml. Cells were fed after 4 days by adding one-half the volume of the complete medium, and then were fed at weekly intervals by complete replacement of the medium until a confluent monolayer was developed. BMSCs were used within 4-6 weeks of establishment. BMSCs prepared by this protocol were reported to be primarily fibroblasts (CD54-positive) with a low proportion of macrophages (CD68-positive). No expression of the endothelial markers CD31 and thrombomodulin was detected.
Either lymphoma cell lines or patient lymphoma cells (1.5 Â 10 6 cells per ml) were adhered to pre-established monolayers of HS-5, or were kept in suspension for 12-24 h. Then, lymphoma cells were carefully removed, with the monolayer of HS-5 kept intact. The purity of the lymphoma cell population was greater than 90% when analyzed by flow cytometry (CD19 vs CD44), and cells were used for experiments as described earlier. 21 For transwell experiments, lymphoma cells were separated from HS-5 by transwell inserts.
The patient lymphoma cells designated as DLBL (diffuse large B-cell lymphoma), FCL (follicular cell lymphoma) and MCL (mantle cell lymphoma) were obtained from diagnostic fresh biopsy-derived lymphoma tissues. This study was conducted in accordance with the protocol approved by the Institutional Review Board. Informed consent was obtained from all patients. After Ficoll-Hypaque purification, the CD19-positive cells were positively isolated by using CD19 microbeads with the autoMACS magnetic cell sorter according to the manufacturer's instructions (Miltenyi Biotec, Inc., Auburn, CA, USA).
Apoptosis detection assay and flow cytometry/enzymelinked immunosorbent assay analysis for BAFF Lymphoma cells were cultured on a complete confluent monolayer of HS-5. After the indicated period of time, lymphoma cells were carefully removed, with the monolayer of HS-5 kept intact. The purity of the lymphoma cell population was greater than 90%. Lymphoma cells were washed and stained with Annexin V FITC in accordance with the manufacturer's procedure (BD Pharmingen, San Diego, CA, USA). Ten thousand events were analyzed by flow cytometry (Becton Dickinson, San Jose, CA, USA) and CellQuest software (BD Biosciences, Mountain View, CA, USA) with at least five independent experiments performed.
Enzyme-linked immunosorbent assay analysis was performed to measure the level of BAFF in the culture and coculture supernatant. Lymphoma cells and BMSCs (3 Â 10 5 cells per ml) alone were seeded onto culture plates for 24 h. For coculture experiments, BMSCs were seeded onto culture plates overnight, and lymphoma lines were added to these BMSC-coated plates the following day. Supernatants harvested from 48-h cultures were tested for soluble BAFF by enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions. The minimum detectable level of BAFF was 0.81-7.43 pg/ml.
To measure the expression of BAFF in lymphoma cells and stromal cells, flow cytometry was performed. Briefly, lymphoma or stromal cells (0.5 Â 10 6 cells per ml) were stained with fluorescein-conjugated anti-BAFF antibody (eBiosciences, San Diego, CA, USA). Cells were acquired, and membrane-bound BAFF was analyzed using a FACScalibur analyzer and CellQuest software (BD Pharmingen).
Antibodies and western blotting
The following monoclonal antibodies were purchased: BAFF (Upstate, Lake Placid, NY, USA) and b-actin (Sigma, St Louis, MO, USA). At the indicated time, cells were collected, washed twice with ice-cold PBS, and lysed in ice-cold lysis buffer containing 50 mM HEPES pH 7.4, 150 mM NaCl, 0.1% Tween-20, 2 mM EDTA, 2 mM EGTA, 1 mM NaF, 0.1 mM NaVO 4 , 5 mg/ml leupeptin, 0.2 mM PMSF and 1 mM dithiothreitol. After 30 min of incubation on ice, the lysates were sonicated and centrifuged at 12 000 g for 15 min at 4 1C. The lysates were quantified using Biorad reagent (Biorad, Hercules, CA, USA). Fifty micrograms of whole cell lysate were separated by 4-12% NuPage gel (Invitrogen, Carlsbad, CA, USA), transferred to polyvinylidene fluoride membrane and blocked with 5% milk in TBS/T. The membrane was then probed with anti-BAFF antibody, washed with TBS/T and incubated with horseradish peroxidase-conjugated anti-mouse secondary antibody for 1 h. Specific bands were developed by means of a chemiluminescence reagent kit (Amersham Life Sciences, Arlington Heights, IL, USA). The blot was subsequently stripped (100 mM betamercaptoethanol, 2% SDS, 62.5 mM Tris, pH 6.7 for 30 min at 50 1C) and reprobed for b-actin. Protein bands were quantified by the Image Quant software program (Molecular Dynamics, Sunnyvale, CA, USA).
Transient transfection of small hairpin RNA (shRNA)
BAFF shRNAs and control (non-silencing) shRNAs were obtained from Cold Spring Harbor Laboratory. For transient expression, cell lines were transfected by electroporation using Nucleofector (Amaxa, Gaithersburg, MD, USA) according to the manufacturer's instructions and using a commercially available transfection instrument (Amaxa, Koeln, Germany). Briefly, HS-5 cells (5 Â 10 6 cells per ml) were suspended in 100 ml of Nucleofector T solution with shRNA duplex (final concentration 1 mM) and then electroporated using program T-001. Cells were cultured in 5 ml of 37 1C pre-warmed medium containing 10% fetal calf serum. On the basis of the expression of green fluorescent protein analyzed by flow cytometry, the transfection efficiency was between 50 and 75%, with a median of 60% (three independent experiments).
Results
Conditioned medium from coculture of lymphoma cells and bone marrow stromal cells, as well as BAFF, protects B lymphoma cells from spontaneous apoptosis and drug-induced apoptosis Our recent study examined the influence of BMSCs on lymphoma cell response to the topoisomerase II inhibitor, mitoxantrone, as well as on the spontaneous apoptosis of primary lymphomas and cell cycle progression. 20, 22 We showed that coculture of B-cell lymphoma cells with bone marrow stroma significantly inhibited mitoxantrone-induced apoptosis. In this study, we first performed experiments analyzing the possible role for a soluble factor in the BMSC protective mechanism, where lymphoma cell lines and primary lymphoma cells were cultured with conditioned medium harvested from cocultures of BMSCs, HS-5 and lymphoma cells. Table 1 shows that apoptosis in response to mitoxantrone in lymphoma cell lines, as well as spontaneous apoptosis in primary lymphoma cells, was suppressed by a medium conditioned by coculturing lymphoma cells and HS-5 cells. This suggests that paracrine soluble factor(s) generated by cell-cell interaction promote lymphoma cell survival. Because of the knowledge that BAFF was shown to be critical for maintenance of normal B-cell homeostasis as well as the survival of malignant B cells, we therefore next examined the role of BAFF in lymphoma cell survival. Recombinant soluble BAFF was tested on apoptosis of primary B lymphoma cells and lymphoma cell lines. As shown in Figure 1a , the addition of BAFF counteracted mitoxantroneinduced apoptosis in the mantle cell lymphoma cell line, Jeko-1 and the large lymphoma cell line SUDHL-10 ( Figure 1a) , and the addition of BAFF elicited a reduction in spontaneous apoptosis and mitoxantrone-induced apoptosis in primary lymphoma cells (Table 1 and Figure 1b) as measured by Annexin V. The ability of BAFF to attenuate apoptosis further suggested that lymphoma cells use BAFF as a survival factor in the bone marrow microenvironment.
High-level expression of BAFF in bone marrow stromal cells and cell adhesion increases BAFF secretion from bone marrow stromal cells
We next characterized the functional significance of BAFF in CAM-DR and survival. We first assessed the presence of BAFF and its production following cell adhesion in human BMSCs and lymphoma cells. We examined the expression of BAFF mRNA using quantitative real-time PCR, cell membrane BAFF expression using flow cytometric analysis, and the protein level of BAFF by immunoblotting in the BMSC cell line HS-5, as well as in the primary BMSCs 263 and 266. As shown in Figure 2a , HS-5 cells have high expression of BAFF mRNA. The amount of BAFF mRNA detected in HS-5 cells was significantly higher than that of lymphoma cells (SUDHL-10, 5.7 ± 0.3 vs 1.7 ± 0.2). We evaluated the protein expression of BAFF by flow cytometric and immunoblot analysis (Figure 2b ). HS-5 cells and primary BMSCs 263 and 266 (data not shown) expressed high levels of BAFF that were easily detected by flow cytometry. In contrast, cell membrane BAFF protein was essentially identical with isotype control, but was barely detectable in the lymphoma cell lines, SUDHL-10 and Jeko-1, and in the three primary lymphoma samples (not shown). Immunoblots using specific anti-BAFF antibody revealed that total lysates from HS-5 cells and 263, 266 BMSCs had higher amounts of BAFF than did SUDHL 10 and Jeko-1 cells (Figure 2c ). To further examine BAFF production, we measured BAFF secretion from lymphoma cells (SUDHL-4, SUDHL-10) and HS-5 cells. Figure 2d shows that essentially no BAFF was detected in the culture medium from SUDHL-4 and SUDHL-10 and that a much higher level of BAFF was seen in HS-5 cells (4200-fold). All these results indicated that bone marrow stroma is most likely the main source of BAFF production in lymphoma bone marrow microenvironment.
Lymphoma cell adhesion-induced BAFF expression in bone marrow stromal cells results from upregulation of BAFF mRNA and requires direct cell-cell contact
We next examined whether BAFF production from human BMSCs would increase when lymphoma cells adhered to HS-5 cells. BAFF concentrations were measured at 0 and 12 h after adhesion of lymphoma cells (SUDHL 4 and 10). As shown in Figure 2d , BAFF concentrations in conditioned coculture medium of HS-5 and lymphoma cells were much higher than that of culture medium from lymphoma alone, or HS-5 alone, implying that lymphoma adhesion to HS-5 cells significantly triggered BAFF expression and its secretion from BMSCs. To define the source of lymphoma cell adhesion-induced BAFF secretion, HS-5 cells were fixed with 0.5% paraformaldehyde before the adhesion of lymphoma cells. As shown in Figure 3a , when SUDHL-10 cells adhered to the fixed HS-5 cells, no BAFF secretion was detected in the medium of paraformaldehyde-fixed HS-5 cells, either in the absence or presence of cell adhesion, and paraformaldehyde fixation abrogated cell adhesion-induced BAFF secretion. These data suggested that the predominant source of adhesion-induced BAFF secretion was from BMSCs rather than from lymphoma cells. To determine the contribution of soluble factors and physical cell-cell contact to increased BAFF expression and secretion by BMSCs, we used a transwell insert and a microporous membrane to allow lymphoma cells to be juxtaposed to HS-5 cells without cell-cell contact. We performed the experiments by incubating lymphoma cells in the transwell insert (upper chamber) with HS-5 in the lower chamber. In a similar way, we examined whether the soluble factors produced by bone marrow stroma and/or lymphoma cells trigger BAFF secretion. As shown in Figure 3b , four separate transwell insert experiments revealed no increase in BAFF secretion. This result implicated that direct cell-cell contact may be essential for adhesion-induced BAFF expression in BMSCs. To further determine whether adhesion-induced BAFF secretion was through transcriptional activation, quantitative real-time reverse transcription-PCR analysis was performed to probe for BAFF mRNA expression following lymphoma cell adhesion to HS-5 cells. Low-level BAFF transcript was observed in either SUDHL-10 cells (Figure 3c ) or SUDHL-4 cells (not shown). In contrast, adhesion of lymphoma cells to HS-5 cells for 12 h induced a 2.8±0.4-fold increase (Figure 3c ). This result indicated that adhesion-induced BAFF secretion was mediated by increased expression of BAFF in BMSCs.
BMSC-derived BAFF protects lymphoma cells from drug-induced apoptosis and spontaneous apoptosis
On account of the functional specificity and significance of BAFF in B-cell survival, and the high level of BAFF production by BMSCs, we anticipated that BMSC-derived BAFF uniquely provides a survival sanctuary for B-cell lymphoma cells to evade or circumvent drug-induced death. We therefore evaluated the role played by BAFF in cell adhesion-dependent regulation of cell survival. Two different approaches were used, aimed at providing direct evidence for a specific role of BAFF in cell adhesion-mediated cell survival. We first validated the role of BAFF in CAM-DR by neutralization of BAFF by TACI-Ig (transmembrane activator and calcium modulator cyclophilin ligand interactor), a soluble fusion protein that binds to BAFF and its homolog APRIL and inhibits their activity. Experiments were performed to assess whether neutralization of BAFF by TACI-Ig would enhance lymphoma cell response to chemotherapy. and overcame CAM-DR in the presence of BMSCs, but also induced lymphoma cell apoptosis, again suggesting that lymphoma cells use BAFF as an autocrine and paracrine survival factor. As it is well known that TACI can bind to the receptors of both BAFF and APRIL, the effect of TACI-Ig could be attributed to blockage of BAFF and/or APRIL. Therefore, we next addressed whether BAFF in BMSCs was specifically required for CAM-DR. We performed BAFF knockdown experiments by using shRNA and examined the changes of BAFF protein, BAFF secretion, and the role of BAFF in CAM-DR. Figure 5 reveals that BAFF shRNA indeed depleted BAFF in HS-5 cells, which was confirmed by immunoblots and enzyme-linked immunosorbent assay. Furthermore, BAFF depletion sensitized SUDHL-10 cells to mitoxantrone and abrogated CAM-DR, supporting the role of BMSC-derived BAFF in B-cell survival and drug resistance.
Discussion
The role of BAFF in B-cell survival and homeostasis is well defined. Regardless of the source of BAFF, its significance in B-cell lymphoma was substantiated by recent emerging reports on elevated BAFF secretion in many B-cell malignancies. 18, 23, 24 Dysfunctional BAFF signaling has been implicated in many B-cell lymphomas with an autocrine loop stimulating lymphoma cell growth and survival, 18, 24 and attenuating tumor cell apoptosis when NHL B cells are exposed to cytotoxic agents. Kern et al. 18 showed that the addition of soluble BAFF or APRIL protected B-CLL cells against spontaneous and drug-induced apoptosis. Conversely, the addition of soluble BCMA-Fc, or anti-BAFF and anti-APRIL antibodies, enhanced B-CLL cell apoptosis. Moreaux et al. 19 provided evidence that BAFF was involved in the survival of primary myeloma cells and it protected myeloma cells from dexamethasone-induced apoptosis. These results indicate that B-CLL and MM cells can be rescued from apoptosis through a process involving BAFF and its receptors. B lymphoma cells deregulate an otherwise physiologic autocrine survival pathway to evade apoptosis. However, the biological role of BAFF in lymphoma pathogenesis within the bone marrow microenvironment is not fully characterized. The origin of BAFF remains undefined, even though an autocrine interaction can be identified in a subset of lymphomas. Furthermore, it is well known that B lymphoma cells in vitro die spontaneously and can be difficult to keep alive in culture. Our and other recent studies have suggested that lymphoma cell survival can be influenced by interactions with non-lymphoma cells in the microenvironment of the bone marrow and in a paracrine pathway. 20, 22, 24 Soluble factors produced by lymphoma cells and adjacent stromal cells, have been implicated in the pathogenesis and progression of lymphomas. We anticipated that BMSCs produce a local high level of BAFF in the bone marrow microenvironment at the location where B-cell longevity is induced or maintained, and where B cells are protected from cytotoxic apoptosis. In this study, we therefore characterized the role of BAFF in regulating lymphoma cell survival and its response to cytotoxic agents in the bone marrow microenvironment. To our knowledge, this is the first report to characterize BAFF, as well as the regulation of its secretion, in the interaction and adhesion of lymphoma cells with BMSCs. More importantly, we further defined the role of BAFF in cell adhesion and stroma-mediated drug resistance and survival. We showed that (1) BMSCs are the main source of BAFF in the bone marrow microenviroment of lymphoma, (2) adhesion of lymphoma cells to BMSCs triggers BAFF secretion through upregulation of mRNA expression and cell-cell contact between lymphoma and stromal cells, and (3) BMSC-derived BAFF is a functional determinant for B lymphoma cell survival in the bone marrow environment.
As BAFF originally was found to be expressed in myeloid lineage cells, such as monocytes, macrophages or dendritic cells, high expression of BAFF in the lymphoma bone marrow microenvironment was anticipated. We found that BAFF secretion in BMSCs is 420-fold higher than in lymphoma cells. This is substantiated by immunohistochemistry showing that bone marrow sections from MM patients stained brightly for BAFF. 25 Although a previous study showed that some lymphoma cells secrete BAFF, we found that the major source of BAFF in the B-cell lymphoma marrow environment is BMSCs. We therefore focused on determining the effect of lymphoma cell adhesion on BAFF secretion in BMSCs, and on the lymphoma cell response to cytotoxic agents. Importantly, a significant increase in BAFF secretion was triggered by lymphoma cell adhesion to BMSCs. As paraformaldehyde fixation of BMSCs significantly inhibited BAFF secretion, adhesion-induced BAFF secretion and protection against mitoxantrone-induced cell death, we concluded that BAFF secretion was primarily from BMSCs rather than from lymphoma cells. This is in agreement with a study on MM, 26 showing that both MM and lymphoma cell adhesion to BMSCs are essential to trigger BAFF secretion by BMSCs. Moreover, experiments analyzing the possible role of a soluble factor and cell-cell contact in adhesion-induced BAFF secretion showed dependence on cell-cell contact, as separation of stromal cells, HS-5 and lymphoma cells by a microporous membrane (transwell insert) did not increase BAFF secretion.
To understand the molecular mechanism of cell adhesioninduced BAFF secretion, we analyzed the effect of lymphoma cell adhesion to BMSC on BAFF gene expression in BMSCs. Using quantitative real-time reverse transcription-PCR, we have found that induction of BAFF secretion in BMSCs by lymphoma cell adhesion was indeed, at least partially, because of an increase in the transcription of the BAFF gene. Using BAFF promoter-reporter constructs harboring at least six NF-kBbinding sites, a recent published report showed that NF-kB is one crucial regulatory element for induction of the BAFF promoter triggered by MM cell adherence to BMSCs. 26 More recently, Fu et al. 27 demonstrated that NF-kB and NFAT are involved in regulating BLyS expression through at least one NF-kB and 2 NFAT binding sites in the BLyS promoter. However, how these transcriptional factors regulate BAFF expression and whether other mechanisms and transcriptional factors are involved, is the object of ongoing studies.
Our earlier studies showed that coculture of B-cell lymphoma cells with bone marrow stroma significantly inhibited mitoxantrone-induced apoptosis. 20 We, in this study, extend our observations to characterize the role of BAFF in CAM-DR. We first observed the cytoprotective effect on spontaneous and mitoxantrone-induced apoptosis by stromal/lymphoma cell coculture conditioned medium, suggesting that soluble factors were adequate to recapitulate the survival benefits afforded by BMSCs. To explore the mechanism underlying the enhanced survival afforded by coculture with BMSCs, we introduced neutralizing TACI-Ig against BAFF in the interaction between stromal cells and lymphoma cells. As shown in Figure 4 , TACI-Ig sensitized SUDHL-10 cells to mitoxantrone and overcame CAM-DR in the presence of stromal cells. However, TACI-Fc showed only minor inhibitory activity on cell survival in the absence of BMSCs, suggesting the role of BAFF in BMSCs. Finally, we specifically depleted BAFF in BMSCs by shRNA and found that BMSC-derived BAFF was indeed involved in CAM-DR in the bone marrow microenvironment. These experiments provided evidence that lymphoma cells used BAFF derived from BMSCs as a paracrine survival factor. This is in accordance with our daily observation; the majority of cells left in the bone marrow after chemotherapy are BMSCs and macrophages, often admixed with residual leukemia/lymphoma cells. We therefore hypothesize that BMSCs and macrophages create niches of local high BAFF availability and provide a sanctuary site for lymphomas. BMSCs are triggered to produce BAFF at sites where B lymphoma cells interact, where longevity is induced and maintained, and where lymphoma cells are protected from apoptosis. Such a hypothesis provides a rationale for interference with the interaction between BMSC-derived BAFF and its cognate lymphoma cells by TACI-Ig or other BAFF inhibitors (or molecules that inhibit BAFF secretion) as a novel therapeutic approach against lymphoma. Given the ability of TACI to enhance apoptosis and overcome CAM-DR, the combination of BAFF inhibitors and cytotoxic drugs might be a more optimal therapeutic treatment regimen against B-cell malignancies.
